Furthermore, it has been shown that bispecific anti-TNF-α/IL-17 antibodies may have superior efficacy and safety in treating rheumatoid arthritis (39), but this has not been demonstrated in another study involving patients with psoriasis arthritis (40). The gene discussed is IL17A; the disease is rheumatoid arthritis.